| Title |
Nab-paclitaxel, docetaxel, or solvent-based paclitaxel in metastatic breast cancer: a cost-utility analysis from a Chinese health care perspective
|
|---|---|
| Published in |
ClinicoEconomics and Outcomes Research: CEOR, May 2015
|
| DOI | 10.2147/ceor.s82194 |
| Pubmed ID | |
| Authors |
George Dranitsaris, Bo Yu, Jennifer King, Satyin Kaura, Adams Zhang |
| Abstract |
Paclitaxel and docetaxel are commonly used for metastatic breast cancer in the People's Republic of China. To improve the safety and efficacy of paclitaxel, an albumin-bound formulation (nab) is now available in the People's Republic of China (Abraxane(®)). To provide health economic data for the key stakeholders, a cost-utility analysis comparing nab-paclitaxel to docetaxel, both as alternatives to paclitaxel, was conducted. A meta-analysis of clinical outcomes Phase III trials comparing nab-paclitaxel (260 mg/m(2) every [q] 3 weeks) or branded docetaxel (100 mg/m(2) q 3 weeks), to solvent-based branded paclitaxel (175 mg/m(2) q 3 weeks) was undertaken to provide safety and clinical data. Resource use data for the delivery of anticancer therapy and for the treatment of grade 3/4 toxicity was collected from a time and motion study conducted in three Chinese cancer centers and from a survey of clinicians. Using the Time Trade-Off technique, health utility estimates were derived from interviewing 28 breast cancer patients from one cancer center in the People's Republic of China. All costs were reported in 2014 US dollars. Nab-paclitaxel had the most favorable safety profile, characterized with the lowest incidence of grade 3/4 neutropenia, febrile neutropenia, anemia, and stomatitis. When the median number of cycles delivered from the clinical trials was applied, nab-paclitaxel had a cost per course of $19,752 compared with $8,940 and $13,741 for paclitaxel and docetaxel, respectively. As an alternative to paclitaxel, the cost per quality-adjusted life-year (QALY) gained with nab-paclitaxel suggested better value than with docetaxel ($57,900 vs $130,600). Nab-paclitaxel appears to be a cost-effective option compared with docetaxel and paclitaxel, for metastatic breast cancer in the People's Republic of China. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 55 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Ecuador | 1 | 2% |
| Unknown | 54 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 8 | 15% |
| Researcher | 6 | 11% |
| Student > Bachelor | 6 | 11% |
| Student > Master | 5 | 9% |
| Student > Doctoral Student | 4 | 7% |
| Other | 9 | 16% |
| Unknown | 17 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 22% |
| Nursing and Health Professions | 6 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 11% |
| Biochemistry, Genetics and Molecular Biology | 3 | 5% |
| Engineering | 3 | 5% |
| Other | 5 | 9% |
| Unknown | 20 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 November 2017.
All research outputs
#7,811,404
of 25,457,297 outputs
Outputs from ClinicoEconomics and Outcomes Research: CEOR
#167
of 525 outputs
Outputs of similar age
#86,228
of 279,093 outputs
Outputs of similar age from ClinicoEconomics and Outcomes Research: CEOR
#5
of 16 outputs
Altmetric has tracked 25,457,297 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 525 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.0. This one has gotten more attention than average, scoring higher than 66% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 279,093 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.